Atlas Trials

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Clinical trial NCT02317991 · COMPLETED

Trial details

NCT number
NCT02317991
Sponsor
SCRI Development Innovations, LLC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Gastroesophageal Cancer
Start date
2015-05-05
Primary completion
2021-05-21
Enrollment
65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.